The Netherlands: Pleco Therapeutics announces €8.7m partnership with Hyloris

Pleco Therapeutics, a biopharmaceutical company developing combination chelating agents to detoxify the cancer micro-environment, has entered into a strategic partnership with Belgium-based and listed Hyloris Pharmaceuticals, a biopharma company reinventing existing medications, to develop and commercialise a Plecoid Agent to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML) and Small Cell…

You must be a HMI Subscriber to view this content.

Subscribe Now »